ArticlePloS one2017
The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 2 syntheses or guidelines pooled it, 228 citations in OpenAlex.
- Changes in Gut Microbiota and Multiple Sclerosis: A Systematic Review.International journal of environmental research and public health · 2023Pooled it
- Gut dysbiosis in rheumatic diseases: A systematic review and meta-analysis of 92 observational studies.EBioMedicine · 2022Pooled it
- Influence of a High-Impact Multidimensional Rehabilitation Program on the Gut Microbiota of Patients with Multiple Sclerosis.International journal of molecular sciences · 2021Trial
- Deconfounded, quantitative microbiome profiling identifies robust multiple sclerosis markers and clinical covariate associations.Gut microbes · 2026Article
- FFAR2 activation induces IL-22-dependent intestinal immune responses to suppress CNS autoimmunity.EMBO molecular medicine · 2026Article
- Integrated multi-omics analysis identifies microbial and metabolic signatures and drivers of CNS autoimmunity.mSystems · 2026Article
- Short-Chain Fatty Acids May Promote Regulatory T Cell Induction to Enhance Maternal Immune Tolerance in Early Pregnancy.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- Short-chain fatty acids and their gut microbial pathways distinguish rheumatoid arthritis in discordant monozygotic twins.Annals of the rheumatic diseases · 2026Article
- Integrated multi-omics analysis identifies microbial and metabolic signatures and drivers of CNS autoimmunity.bioRxiv : the preprint server for biology · 2026Article
- Gut microbiota and gut-derived metabolites in defining multiple sclerosis phenotypic continuum.Frontiers in immunology · 2026Review
- Dose-dependent protective effects ofFrontiers in pharmacology · 2026Article
- Propionate attenuates osteoarthritis progression by regulating the gut-joint axis.Frontiers in immunology · 2026Article
- SCFAs' pleiotropic role in pathogenesis and salutogenesis: mechanisms in exacerbation and regulation of inflammation and fibrosis from gut to host.Journal of medical microbiology · 2026Review
- Fatty acid metabolism-an emerging regulatory node in T-cell immunometabolism.Clinical & translational immunology · 2026Review
- Gut microbiota in regulatory T cell generation and function: mechanisms and health implications.Gut microbes · 2025Review
- Molecular mechanisms of bone metastasis in breast cancer based on transcriptomic and microbiomic analysis.Cancer causes & control : CCC · 2025Article
- Microbiota-Derived SCFAs in Multiple Sclerosis: From Immune Priming to Neurodegeneration.Molecular neurobiology · 2025Review
- Gut microbiota modulates CNS barrier function in murine model for multiple sclerosis.Fluids and barriers of the CNS · 2025Article
- Linking Nutrients to Multiple Sclerosis Pathogenesis: Biological Evidence and Clinical Implications.Nutrients · 2025Review
- Gut microbiota-derived short-chain fatty acids and their role in human health and disease.Nature reviews. Microbiology · 2025Review
85 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune diseases are influenced by both genetic and environmental factors. The gut environment has attracted much attention as an essential component that modulates immune responses, and therefore immune-mediated disorders, such as autoimmune diseases. Growing evidence suggests that microbiota and their metabolites are critical factors for immune modulation. Recently, we reported that the microbiome in patients with multiple sclerosis, an autoimmune disease targeting the myelin sheath of the central nervous system, is characterized by a reduction of bacteria belonging to Clostridia clusters IV and XIVa, which are potent producers of short-chain fatty acids (SCFAs) by fermentation of indigestible carbohydrates. In the present study, we investigated the role of SCFAs in the regulation of inflammation. We demonstrated that oral administration of SCFAs ameliorated the disease severity of systemic autoimmune inflammatory conditions mediated by lymphocytes such as experimental autoimmune encephalitis and collagen-induced arthritis. Amelioration of disease was associated with a reduction of Th1 cells and an increase in regulatory T cells. In contrast, SCFAs contributed to the exaggeration of K/BxN serum transfer arthritis, representing the effector phase of inflammation in rheumatoid arthritis. An increased understanding of the effect of microbiota metabolites will lead to the effective treatment and prevention of systemic inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.